Date: 2014-08-20
Type of information: R&D agreement
Compound:
Company: AstraZeneca (UK) Mitsubishi Tanabe Pharma Corporation (Japan)
Therapeutic area: Metabolic diseases - Renal diseases - Kidney diseases
Type agreement: R&D agreement
Action mechanism:
Disease: diabetic nephropathy
Details: * On August 20, 2014, AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) announced a three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development. The collaboration will span from target selection up to the delivery of small molecule candidate drugs. Targets from each company’s early research portfolios have been identified as approaches of common interest and additional targets may be included under the collaboration at a later stage, if mutually desired. The research will be performed in parallel at AstraZeneca’s Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Mölndal, Sweden, and at MTPC’s facilities in Japan. The parties believe that the collaboration will yield high quality candidate drugs much faster than working alone.
Financial terms: There is no financial commitment for the research involved and each party will contribute equal resource at their own cost.
Latest news:
